Voyageur PharmaceuticalsVYYRF +7.71%18 EV-to-FCF is -12.96 as of Jun. 29, 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 559 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks worse than 178890.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Voyageur Pharmaceuticals's Enterprise Value is $18.99 Mil.
Voyageur Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 was $-1.47 Mil. Therefore, Voyageur Pharmaceuticals's EV-to-FCF for today is -12.96.
The historical rank and industry rank for Voyageur Pharmaceuticals's EV-to-FCF or its related term are showing as below:
VYYRF'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.96 Med: 0 Max: 0
Current: -12.96
VYYRF's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.02
vs VYYRF: -12.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Voyageur Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Voyageur Pharmaceuticals's share price for today is $0.095.
Voyageur Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Voyageur Pharmaceuticals EV-to-FCF Related Terms
Voyageur Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyageur Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Voyageur Pharmaceuticals's EV-to-FCF falls into.
Voyageur Pharmaceuticals's current Enterprise Value is $18.99 Mil.
Voyageur Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyageur Pharmaceuticals (VYYRF) has a EV-to-FCF of -12.96 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is Voyageur Pharmaceuticals' EV-to-FCF too high?
Voyageur Pharmaceuticals' current EV-to-FCF is -12.96. Based on the distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #999999 out of 559 companies for EV-to-FCF. This places Voyageur Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Voyageur Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current EV-to-FCF is -12.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current EV-to-FCF of -12.96. The current EV-to-FCF is -12.96. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current EV-to-FCF is -12.96 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score
Get the complete analysis for VYYRF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYYRF has been successfully added to your 
